Cebranopadol as a Novel Promising Agent for the Treatment of Pain |
| |
| Authors: | Wojciech Ziemichod Jolanta Kotlinska Ewa Gibula-Tarlowska Natalia Karkoszka Ewa Kedzierska |
| |
| Affiliation: | Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4a Doktora Witolda Chodźki Street, 20-400 Lublin, Poland; (J.K.); (E.G.-T.); (N.K.); (E.K.) |
| |
| Abstract: | Opioids are used to treat pain, but despite their effectiveness, they possess several side effects such as respiratory depression, tolerance and physical dependence. Cebranopadol has been evaluated as a solution to this problem. The compound acts on the mu opioid receptor and the nociceptin/orphanin receptor and these receptors co-activation can reduce opioid side-effects without compromising analgesia. In the present review, we have compiled information on the effects of cebranopadol, its pharmacokinetics, and clinical trials involving cebranopadol, to further explore its promise in pain management. |
| |
| Keywords: | cebranopadol pain opioids nociceptin acute-pain chronic-pain orphanin |
|
|
